Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
J Intern Med ; 287(3): 252-262, 2020 03.
Article in English | MEDLINE | ID: mdl-31621967

ABSTRACT

Mass extinctions occur frequently in natural history. While studies of animals that became extinct can be informative, it is the survivors that provide clues for mechanisms of adaptation when conditions are adverse. Here, we describe a survival pathway used by many species as a means for providing adequate fuel and water, while also providing protection from a decrease in oxygen availability. Fructose, whether supplied in the diet (primarily fruits and honey), or endogenously (via activation of the polyol pathway), preferentially shifts the organism towards the storing of fuel (fat, glycogen) that can be used to provide energy and water at a later date. Fructose causes sodium retention and raises blood pressure and likely helped survival in the setting of dehydration or salt deprivation. By shifting energy production from the mitochondria to glycolysis, fructose reduced oxygen demands to aid survival in situations where oxygen availability is low. The actions of fructose are driven in part by vasopressin and the generation of uric acid. Twice in history, mutations occurred during periods of mass extinction that enhanced the activity of fructose to generate fat, with the first being a mutation in vitamin C metabolism during the Cretaceous-Paleogene extinction (65 million years ago) and the second being a mutation in uricase that occurred during the Middle Miocene disruption (12-14 million years ago). Today, the excessive intake of fructose due to the availability of refined sugar and high-fructose corn syrup is driving 'burden of life style' diseases, including obesity, diabetes and high blood pressure.


Subject(s)
Biological Evolution , Climate Change , Droughts , Energy Metabolism/physiology , Fructose/metabolism , Animals , Diet , Extinction, Biological , Hominidae , Humans , Mutation
2.
Ann Nutr Metab ; 66 Suppl 3: 10-3, 2015.
Article in English | MEDLINE | ID: mdl-26088040

ABSTRACT

Dehydration, a condition that characterizes excessive loss of body water, is well known to be associated with acute renal dysfunction; however, it has largely been considered reversible and to be associated with no long-term effects on the kidney. Recently, an epidemic of chronic kidney disease has emerged in Central America in which the major risk factor seems to be recurrent heat-associated dehydration. This has led to studies investigating whether recurrent dehydration may lead to permanent kidney damage. Three major potential mechanisms have been identified, including the effects of vasopressin on the kidney, the activation of the aldose reductase-fructokinase pathway, and the effects of chronic hyperuricemia. The discovery of these pathways has also led to the recognition that mild dehydration may be a risk factor in progression of all types of chronic kidney diseases. Furthermore, there is some evidence that increasing hydration, particularly with water, may actually prevent CKD. Thus, a whole new area of investigation is developing that focuses on the role of water and osmolarity and their influence on kidney function and health.


Subject(s)
Dehydration/complications , Heat Exhaustion/complications , Renal Insufficiency, Chronic/etiology , Vasopressins/metabolism , Aldehyde Reductase/metabolism , Central America , Dehydration/physiopathology , Dehydration/therapy , Disease Progression , Fluid Therapy , Fructokinases/metabolism , Humans , Hyperuricemia/complications , Metabolic Networks and Pathways , Osmolar Concentration , Recurrence , Renal Insufficiency, Chronic/prevention & control
3.
Free Radic Res ; 48(11): 1342-54, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25119790

ABSTRACT

The potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated. Tubular proteinuria and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats. Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl ß-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels. Studies were also conducted in renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups. Maleate induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture. In addition, maleate treatment reduced oxygen consumption in ADP-stimulated mitochondria and diminished respiratory control index when using malate/glutamate as substrate. The activities of both complex I and aconitase were also diminished. All the above-described alterations were prevented by curcumin. It is concluded that curcumin is able to attenuate in vivo maleate-induced nephropathy and in vitro cell damage. The in vivo protection was associated to the prevention of oxidative stress and preservation of mitochondrial oxygen consumption and activity of respiratory complex I, and the in vitro protection was associated to the prevention of ROS production.


Subject(s)
Curcumin/pharmacology , Electron Transport Complex I/metabolism , Hemodynamics/drug effects , Kidney Diseases/prevention & control , Mitochondria/drug effects , Oxidative Stress/drug effects , Oxygen Consumption/drug effects , Aldehyde Reductase/antagonists & inhibitors , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Apoptosis/drug effects , Biomarkers/analysis , Blotting, Western , Electron Transport Complex I/drug effects , Enzyme Inhibitors/toxicity , Kidney Diseases/chemically induced , LLC-PK1 Cells , Lipid Peroxidation/drug effects , Male , Maleates/toxicity , Mitochondria/metabolism , Oxidation-Reduction , Rats , Rats, Wistar , Reactive Oxygen Species/metabolism , Swine
4.
Pac Health Dialog ; 20(1): 11-6, 2014 Mar.
Article in English | MEDLINE | ID: mdl-25928990

ABSTRACT

Pacific people (especially Micronesian and Polynesian) have some of the highest rates of obesity and diabetes in the world that largely developed since the introduction of western culture and diet. Recent studies suggest that much of the risk relates to the excessive intake of sugar (sucrose) and carbohydrates, leading to a type of fat storage syndrome (metabolic syndrome). Here we discuss some of the environmental. genetic and epigenetic reasons why this group might be especially prone to developing obesity and diabetes compared to other ethnic groups. Indirect evidence suggests that the higher endogenous uric acid levels in the Polynesian-Micronesian population may represent a predisposing factor for the development of obesity and diabetes in the context of Western diets and lifestyles. Pacific people may be an ideal group to study the role of "thrifty genes" in the pathogenesis of the current obesity epidemic.


Subject(s)
Diet , Gene-Environment Interaction , Metabolic Syndrome/ethnology , Metabolic Syndrome/epidemiology , Metabolic Syndrome/genetics , Native Hawaiian or Other Pacific Islander , Cultural Characteristics , Diabetes Mellitus, Type 2/epidemiology , Diabetes Mellitus, Type 2/ethnology , Diabetes Mellitus, Type 2/genetics , Dietary Carbohydrates/administration & dosage , Dietary Carbohydrates/adverse effects , Dietary Sucrose/administration & dosage , Dietary Sucrose/adverse effects , Epigenomics , Feeding Behavior , Fructose/administration & dosage , Fructose/adverse effects , Humans , Obesity/epidemiology , Obesity/ethnology , Obesity/genetics , Risk Factors , Uric Acid/metabolism
5.
Exp Clin Endocrinol Diabetes ; 121(9): 535-8, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23934680

ABSTRACT

OBJECTIVE: To evaluate the effect of sodium and fructose restriction on mitochondrial DNA (mtDNA) content and systemic oxidative stress in a sample of overweight and pre hypertensive subjects. MATERIAL/METHODS: Data and blood samples were collected from 36 overweight and pre hypertensive patients randomly assigned to either an isocaloric (with respect to baseline) low sodium-fructose diet or an isocaloric low sodium diet. Patients were followed for 8 weeks. We measured mitochondrial DNA (mtDNA) content from peripheral blood white cells by Real-time PCR and plasma malondialdehyde (MDA) and 2,4-dinitrophenylhydrazine (DNPH) as markers of reactive oxygen species (ROS). RESULTS: Compared to baseline, at week 8 there was a continued and significant increase in mtDNA in both the low sodium diet group [2.4 vs. 13.1 (relative copy number), p<0.05] and the low sodium diet-fructose group (1.9 vs. 147.2, p<0.05). By week 8 there was a continued decrease in plasma DNPH levels in the low sodium diet group (4.6 vs. 2.6, p<0.05) and in the low sodium diet-fructose group (5.8 vs. 2.2, p<0.05). No significant differences were found with MDA. CONCLUSION: Our studies suggest that simple dietary measures such as reducing salt with or without restricting fructose can increase mtDNA and improve markers of oxidative stress.


Subject(s)
DNA, Mitochondrial/metabolism , Diet, Carbohydrate-Restricted , Diet, Sodium-Restricted , Fructose , Leukocytes/metabolism , Overweight/blood , Oxidative Stress , Adult , Energy Intake , Energy Metabolism , Female , Humans , Male , Middle Aged , Real-Time Polymerase Chain Reaction
6.
Int J Obes (Lond) ; 34(3): 454-61, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20029377

ABSTRACT

BACKGROUND: Excessive fructose intake causes metabolic syndrome in animals and can be partially prevented by lowering the uric acid level. We tested the hypothesis that fructose might induce features of metabolic syndrome in adult men and whether this is protected by allopurinol. METHODS: A randomized, controlled trial of 74 adult men who were administered 200 g fructose daily for 2 weeks with or without allopurinol. Primary measures included changes in ambulatory blood pressure (BP), fasting lipids, glucose and insulin, homeostatic model assessment (HOMA) index, body mass index and criteria for metabolic syndrome. RESULTS: The ingestion of fructose resulted in an increase in ambulatory BP (7+/-2 and 5+/-2 mm Hg for systolic (SBP) and diastolic BP (DBP), P<0.004 and P<0.007, respectively). Mean fasting triglycerides increased by 0.62+/-0.23 mmol l(-1) (55+/-20 mg per 100 ml), whereas high-density lipoprotein cholesterol decreased by 0.06+/-0.02 mmol l(-1) (2.5+/-0.7 mg per 100 ml), P<0.002 and P<0.001, respectively. Fasting insulin and HOMA indices increased significantly, whereas plasma glucose level did not change. All liver function tests showed an increase in values. The metabolic syndrome increased by 25-33% depending on the criteria. Allopurinol lowered the serum uric acid level (P<0.0001) and prevented the increase in 24-h ambulatory DBP and daytime SBP and DBP. Allopurinol treatment did not reduce HOMA or fasting plasma triglyceride levels, but lowered low-density lipoprotein cholesterol relative to control (P<0.02) and also prevented the increase in newly diagnosed metabolic syndrome (0-2%, P=0.009). CONCLUSIONS: High doses of fructose raise the BP and cause the features of metabolic syndrome. Lowering the uric acid level prevents the increase in mean arterial blood pressure. Excessive intake of fructose may have a role in the current epidemics of obesity and diabetes.


Subject(s)
Allopurinol/therapeutic use , Antimetabolites/therapeutic use , Fructose/adverse effects , Hypertension/blood , Metabolic Syndrome/blood , Uric Acid/blood , Adult , Aged , Blood Glucose/metabolism , Blood Pressure/drug effects , Blood Pressure Monitoring, Ambulatory , Body Mass Index , Fasting/blood , Fructose/administration & dosage , Fructose/blood , Humans , Hypertension/drug therapy , Insulin/blood , Lipids/blood , Male , Metabolic Syndrome/chemically induced , Metabolic Syndrome/prevention & control , Middle Aged , Pilot Projects , Triglycerides/blood
7.
Am J Physiol Renal Physiol ; 294(1): F84-92, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17942570

ABSTRACT

Since marked renal vasoconstriction is observed in angiotensin II (ANG II)-mediated hypertensive rats, we studied the possible interaction between ANG II and adenosine in this model. ANG II was infused into male Wistar rats through osmotic minipumps (435 ng x kg(-1) x min(-1)) for 14 days. In sham and ANG II groups, renal tissue and interstitial adenosine were measured; both increased to a similar twofold extent in the ANG II-treated rats (31.40 +/- 4 vs. 62.0 +/- 8.4 nM, sham vs. ANG II, interstitial adenosine; P< 0.001). The latter decreased by 47% with the specific blockade of 5'-nucleotidase. Glomerular hemodynamics demonstrated marked renal vasoconstriction in the angiotensin-treated group, which was reverted by an adenosine A(1)-receptor antagonist (8-cyclopentyl-1,3-dipropylxanthine, 10 mug.kg(-1) x min(-1)). 5'-Nucleotidase and adenosine deaminase (ADA) activities were measured in the cytosolic and membrane fractions. Only the membrane ADA activity decreased from 1,202 +/- 80 to 900 +/- 50 mU/mg protein in the ANG II-treated rats (P< 0.05), as well as in their protein and mRNA expression. Despite the adenosine elevation, A(1) and A(2b) receptor protein did not change; in contrast, downregulation was observed in A(2a) receptor and upregulation in A(3) receptor. A similar pattern was found in the cortex and in the medulla; mRNA significantly decreased only in the A(3) receptor in both segments. These results suggest that the elevation of renal tissue and interstitial adenosine contributes to the renal vasoconstriction observed in the ANG II-induced hypertension and that it is mediated by a decrease in the activity and expression of ADA, increased production of adenosine, and an induced imbalance in adenosine receptors.


Subject(s)
Adenosine/metabolism , Angiotensin II/adverse effects , Hypertension/chemically induced , Hypertension/metabolism , Kidney Cortex/metabolism , 5'-Nucleotidase/metabolism , Adenosine Deaminase/metabolism , Angiotensin II/antagonists & inhibitors , Angiotensin II/pharmacology , Animals , Blood Pressure/drug effects , Disease Models, Animal , Male , Proteinuria/metabolism , Purinergic P1 Receptor Antagonists , RNA, Messenger/metabolism , Rats , Rats, Wistar , Receptors, Purinergic P1/metabolism , Vasoconstrictor Agents/adverse effects
8.
Kidney Int ; 69(10): 1722-5, 2006 May.
Article in English | MEDLINE | ID: mdl-16598194

ABSTRACT

Uric acid is strongly associated with cardiovascular and renal disease, but is usually not considered to have a causal role. However, recent experimental, epidemiological, and clinical studies provocatively suggest that uric acid may contribute to the development of hypertension, metabolic syndrome, and kidney disease in some patients. Clinical studies are urgently needed to examine this important possibility.


Subject(s)
Cardiovascular Diseases/etiology , Kidney Diseases/etiology , Uric Acid/metabolism , Animals , Humans
9.
Hypertension ; 36(4): 642-7, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11040251

ABSTRACT

Cyclosporine toxicity mainly affects kidney and liver function. We have previously shown that cyclosporine nephrotoxicity alters kidney nitric oxide synthase mRNA pattern of expression. To determine if nitric oxide synthase expression changes are mediated directly by cyclosporine or by secondary hemodynamic alterations induced by cyclosporine, we evaluated if these effects are tissue specific and if nifedipine-induced vasodilation prevents these alterations. Uninephrectomized Wistar rats treated for 7 days with olive oil, cyclosporine (30 mg/kg), nifedipine (3 mg/kg), and nifedipine+cyclosporine were studied. In vehicle and cyclosporine groups, the gene expression of the neuronal, inducible, and endothelial nitric oxide synthases in cerebellum, heart, intestine, liver, renal cortex, and medulla was evaluated. The administration of cyclosporine was associated with nephrotoxicity and hepatotoxicity, increased endothelial nitric oxide synthase mRNA levels in renal cortex and liver, and a decrease in inducible nitric oxide synthase and neuronal nitric oxide synthase in renal medulla. The mRNA levels of the 3 nitric oxide synthase isoforms were not affected in any other tissue. Nifedipine did not alter nitric oxide synthase expression in the control group but prevented changes associated with cyclosporine. These results suggest that cyclosporine-induced changes in the pattern of expression of the nitric oxide synthases may be secondary to its hemodynamic effects.


Subject(s)
Cyclosporine/pharmacology , Nifedipine/pharmacology , Nitric Oxide Synthase/drug effects , Nitric Oxide Synthase/genetics , RNA, Messenger/drug effects , Animals , Body Weight/drug effects , Cyclosporine/toxicity , Glomerular Filtration Rate/drug effects , Glyceraldehyde-3-Phosphate Dehydrogenases/metabolism , Isoenzymes/genetics , Isoenzymes/metabolism , Kidney Cortex/drug effects , Kidney Cortex/enzymology , Kidney Medulla/drug effects , Kidney Medulla/enzymology , Liver/drug effects , Liver/enzymology , Liver Function Tests , Male , Nephrectomy , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type I , Nitric Oxide Synthase Type II , Nitric Oxide Synthase Type III , Organ Specificity , RNA, Messenger/metabolism , Rats , Rats, Wistar
10.
Am J Physiol ; 277(3): F464-71, 1999 09.
Article in English | MEDLINE | ID: mdl-10484530

ABSTRACT

Cyclosporin A (CsA)-induced renal vasoconstriction (RV) is attributed to an imbalance in vasoactive factors release. Dexamethasone (Dex) exerts a renal vasodilatory effect by a mechanism not yet characterized. This study evaluates whether the effect of Dex is mediated by NO and whether it prevents CsA-induced RV. Micropuncture studies were performed in six groups of uninephrectomized rats treated for 7 days with the following: vehicle (Veh); Veh + 4 mg/kg dexamethasone (Veh+Dex); 30 mg/kg CsA; CsA+Dex; vehicle + 10 mg/kg nitro-L-arginine methyl ester (Veh+L-NAME); and Veh+Dex+L-NAME. NO synthase (NOS) isoform mRNA levels were evaluated in renal cortex and medulla by semiquantitative RT-PCR analysis in the first four groups. Dex produced renal vasodilation, which was blocked by concomitant L-NAME administration, and the effect of Dex was associated with higher cortical and medullary endothelial NOS (eNOS) and cortical inducible NOS (iNOS) mRNA levels. In the CsA group, Dex prevented RV, restoring glomerular hemodynamics to control values. These changes were associated with further enhancement of eNOS and restoration of medullary iNOS and neuronal NOS (nNOS) expression. We conclude that Dex prevents CsA-induced RV, and its vasodilator effect could be mediated by increased intrarenal generation of NO, secondary to enhanced expression of eNOS and iNOS.


Subject(s)
Dexamethasone/pharmacology , Glucocorticoids/pharmacology , Kidney Glomerulus/blood supply , Kidney Glomerulus/physiology , Nitric Oxide Synthase/physiology , Renal Circulation/drug effects , Renal Circulation/physiology , Animals , Cyclosporine/pharmacology , Enzyme Inhibitors/pharmacology , Gene Expression Regulation, Enzymologic/drug effects , Gene Expression Regulation, Enzymologic/physiology , Male , Nephrectomy , Nitric Oxide Synthase Type III , Rats , Rats, Wistar , Vasoconstriction/drug effects , Vasoconstriction/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...